Abstract
Lichen planus (LP)-like eruptions have been reported in patients under anti-tumour necrosis factor-α (TNF-α) treatment [1]. Recently, interleukin 17 (IL-17) inhibitor treatment has also been linked to the induction of LP and lichenoid eruptions [2–6]. Here, we report two additional cases of oral and mucocutaneous LP after secukinumab therapy for psoriasis and briefly review the referenced literature on this phenomenon.Case 1 was a 63-year-old male patient who began secukinumab for treatment of severe [...]